DrugPatentWatch Database Preview

Ucb Inc Company Profile

UCB INC has forty approved drugs.

There are nineteen US patents protecting UCB INC drugs.

There are three hundred and sixty-nine patent family members on UCB INC drugs in fifty-one countries and forty-four supplementary protection certificates in fifteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-003	May 12, 2016		RX	Yes	No	6,784,197	Start Trial	Y	Y		Start Trial
Ucb Inc	VIMPAT	lacosamide	SOLUTION;ORAL	022255-001	Apr 20, 2010		RX	Yes	Yes	RE38551	Start Trial	Y	Y		Start Trial
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-002	May 12, 2016		RX	Yes	No	6,911,461	Start Trial	Y	Y		Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	UNIRETIC	hydrochlorothiazide; moexipril hydrochloride	TABLET;ORAL	020729-003	Feb 14, 2002	4,743,450	Start Trial
Ucb Inc	KEPPRA	levetiracetam	INJECTABLE;INTRAVENOUS	021872-001	Jul 31, 2006	4,943,639*PED	Start Trial
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-003	Nov 30, 1999	4,943,639*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	1000 mg	➤ Subscribe	2007-01-24
➤ Subscribe	Tablets	50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2012-10-29
➤ Subscribe	Extended-release Tablets	1000 mg	➤ Subscribe	2011-01-07
➤ Subscribe	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg	➤ Subscribe	2004-01-15
➤ Subscribe	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr	➤ Subscribe	2013-11-26
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2012-10-29
➤ Subscribe	Injection	10 mg/mL, 20 mL	➤ Subscribe	2016-06-30
➤ Subscribe	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	➤ Subscribe	2005-12-27

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0888289	C00888289/01	Switzerland	Start Trial	PRODUCT NAME: LACOSAMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 59004 28.08.2009
1452524	10/2016	Austria	Start Trial	PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
0888289	09C0006	France	Start Trial	PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.